Serelaxin as a novel therapeutic opposing fibrosis and contraction in lung diseases

Maggie Lam, Simon G. Royce, Chrishan S. Samuel, Jane E. Bourke

PII: S0163-7258(18)30029-9
DOI: https://doi.org/10.1016/j.pharmthera.2018.02.004
Reference: JPT 7185

To appear in:

Please cite this article as: Maggie Lam, Simon G. Royce, Chrishan S. Samuel, Jane E. Bourke , Serelaxin as a novel therapeutic opposing fibrosis and contraction in lung diseases. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Jpt(2018), https://doi.org/10.1016/j.pharmthera.2018.02.004

P&T 23341

*BIOMEDICINE DISCOVERY INSTITUTE AND DEPARTMENT OF PHARMACOLOGY; AND †DEPARTMENT OF MEDICINE, CENTRAL CLINICAL SCHOOL, MONASH UNIVERSITY, MELBOURNE, AUSTRALIA

Serelaxin as a novel therapeutic opposing fibrosis and contraction in lung diseases

Maggie Lam*, Simon G Royce†, Chrishan S Samuel*, Jane E Bourke*

Email: jane.bourke@monash.edu

Phone: +61 (0)439 348 877

Mail: 9 Ancora Imparo Way, Room B112, Clayton Campus, VIC 3800, Australia

Conflict of Interest
The authors declare that there are no conflicts of interest.